Bio-Matrix Scientific Group, Inc. (OTCPINK: BMSN) saw its share volume skyrocket on May 12th with 127,306,136 shares exchanging hands, 2.7 times higher than its three month daily average of 46,941,604 shares.
This growth in volume comes after Regen BioPharma Inc., a majority owned subsidiary of Bio-Matrix Scientific Group Inc., announced an update on its IND # 15376 for use of HemaXellerate I(TM) in treatment of patients with drug refractory aplastic anemia.
The Company reports the FDA accepted the clinical protocol and the product manufacturing information provided, however, clarification on animal safety studies was requested.
"Given the HemaXellerate I(TM) product is derived from the patient's own fat tissue, and numerous key opinion leaders support clinical entry of our product, as demonstrated by our peer reviewed publication http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf., we are confident the safety studies the FDA requested clarification on can be addressed in a timely fashion," stated Thomas Ichim, Regen's Chief Scientific Officer and Board Member.
"The role of the FDA is to ensure the highest standards of safety for new products. We view the requested clarifications from the FDA in regards to safety studies as part of the normal process of FDA submission. Given that the HemaXellerate I™ possesses the potential to treat multiple conditions, we view the demonstration of safety as a fundamental step, which will position the Company to expand use of this 'stem cell drug' for multiple other indications," noted David Koos, the Company's Chairman & CEO. "Having passed the clinical trial protocol approval and the manufacturing approval, are major milestones for Regen."
BMSN closed at $.0033, 37.5% higher than its previous close of $.0024.
PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:
Cellceutix Corp. Reports Update On Brilacidin Clinical Trial
Cellceutix Corp. (OTCQB: CTIX) saw its share volume soar on May 12th with 552,484 shares exchanging hands, significantly higher than its three month daily average of 194,928 shares.
This surge in volume comes after Cellceutix Corporation reported an update on its clinical trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
"As we are advancing in this ABSSSI trial, our acquisition of Brilacidin is confirming our initial assessments and expectations of the compound," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "We are well on our way towards fruition of our goals set for this drug. Between the progress in the ABSSSI trial and our recently announced studies in gram-negative infections, we have greater confidence that Cellceutix now has one of the most formidable arsenals of antibiotic compounds in all of pharma, whether big or small."
CTIX closed at $1.78, 4.7% higher than its previous close of $1.70.
Monitise Share Volume Remains Strong
Monitise PLC (OTCPINK: MONIF) saw its share volume remain strong on May 12th with 3,902,573 shares exchanging hands, right on par with its three month daily average share volume of 3,724,934 shares.
With no recent news on the company, let’s look at what we do know:
Monitise plc, a technology and services company, provides mobile banking, payments, and commerce solutions for financial institutions, payments companies, retailers, mobile network operators, and other service providers in the United Kingdom, the United States, India, and the Asia Pacific. Its core products include Bank Anywhere, a mobile banking service allowing consumers to access their bank accounts and finances anywhere; Pay Anyone, which enables SMEs to accept card payments anytime, anywhere, or allows consumers to pay bills and send money internationally; and Buy Anything, a mobile commerce market that enable consumers for mobile shopping on their smart phones. The company also offers implementation, design and development, adoption, support, and managed services.
MONIF closed at $1.075, 1.42% higher than its previous close of $1.06.
WMI Holdings Corp Sees Decrease In Share Volume
WMI Holdings Corp (OTCQB: WMIH) saw its share volume continue to decline on May 12th with 238,808 shares exchanging hands, significantly lower than its three month daily average volume of 479,243 shares.
MI Holdings Corp., through its subsidiary, WM Mortgage Reinsurance Company, Inc., is engaged in reinsurance business with respect to mortgage insurance in runoff mode.
WMIH closed at $2.68, 1.83% lower than its previous close of $2.73.
Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.pennypickalerts.com
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.